NOK 1.9
(-5.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 300.25 Million NOK | -8.38% |
2022 | 327.7 Million NOK | -4.03% |
2021 | 341.47 Million NOK | 266.39% |
2020 | 93.19 Million NOK | 13.01% |
2019 | 82.46 Million NOK | 81.63% |
2018 | 45.4 Million NOK | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 Q3 | - NOK | -100.0% |
2023 Q1 | - NOK | -100.0% |
2023 Q4 | 300.25 Million NOK | 0.0% |
2023 FY | 300.25 Million NOK | -8.38% |
2023 Q2 | 321.5 Million NOK | 0.0% |
2022 FY | 327.7 Million NOK | -4.03% |
2022 Q4 | 327.7 Million NOK | 0.0% |
2022 Q2 | 327.91 Million NOK | 0.0% |
2021 Q2 | 365.17 Million NOK | 0.0% |
2021 FY | 341.47 Million NOK | 266.39% |
2021 Q4 | 341.47 Million NOK | 0.0% |
2020 FY | 93.19 Million NOK | 13.01% |
2020 Q4 | 93.19 Million NOK | 0.0% |
2019 FY | 82.46 Million NOK | 81.63% |
2018 FY | 45.4 Million NOK | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Aqua Bio Technology ASA | 34.42 Million NOK | -772.076% |
ArcticZymes Technologies ASA | 339.32 Million NOK | 11.515% |
BerGenBio ASA | 174.33 Million NOK | -72.227% |
Hofseth BioCare ASA | 390.11 Million NOK | 23.036% |
PCI Biotech Holding ASA | 44.05 Million NOK | -581.615% |
Thor Medical ASA | 330.83 Million NOK | 9.244% |
Ultimovacs ASA | 349.03 Million NOK | 13.978% |